Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?

Author(s): Temitope O. Lawal, Kapil K. Soni, Brian J. Doyle, Bolanle A. Adeniyi, Gail B. Mahady

Journal Name: Current Bioactive Compounds

Volume 8 , Issue 3 , 2012

Become EABM
Become Reviewer
Call for Editor


The discovery of Helicobacter pylori (H. pylori), the curved or spiral shaped bacteria, as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer was one the most significant discoveries in gastroenterology of the twentieth century. Helicobacter infections promote infiltration of the gastric mucosa by neutrophils, macrophages, and T and B lymphocytes, and leaves the host prone to complications resulting from chronic inflammation. If left untreated, persistent gastrointestinal infections and chronic gastritis may evolve into more severe diseases, such as peptic ulcer or atrophic gastritis. In addition, infection with H. pylori increases the risk of developing gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Helicobacter pylori infections are of great concern worldwide due to increasing antimicrobial resistance and high re-infection rates. In the 1990’s scientific evaluation of natural products and ethnomedicines for the treatment of H. pylori infections began in earnest, and many natural products have been investigated over the past 20 years with promising in vitro results. This review highlights these achievements and the classes of naturally occurring compounds with activity against H. pylori. It also points out the critical need of new treatments for H. pylori infections due to increasing global resistance.

Keywords: Helicobacter pylori, ethnomedicine, gastritis, natural products, peptic ulcer disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 04 September, 2012
Page: [266 - 276]
Pages: 11
DOI: 10.2174/157340712802762447
Price: $65

Article Metrics

PDF: 12